Yousif Capital Management LLC Has $4.19 Million Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Yousif Capital Management LLC decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 18.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 34,422 shares of the medical equipment provider’s stock after selling 7,896 shares during the period. Yousif Capital Management LLC’s holdings in Zimmer Biomet were worth $4,189,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. PFG Advisors grew its holdings in shares of Zimmer Biomet by 4.6% in the 4th quarter. PFG Advisors now owns 1,899 shares of the medical equipment provider’s stock valued at $231,000 after buying an additional 84 shares during the period. Quent Capital LLC grew its holdings in shares of Zimmer Biomet by 21.6% in the 4th quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock valued at $63,000 after buying an additional 92 shares during the period. Pinnacle Associates Ltd. lifted its position in Zimmer Biomet by 5.0% in the 3rd quarter. Pinnacle Associates Ltd. now owns 2,020 shares of the medical equipment provider’s stock valued at $227,000 after acquiring an additional 97 shares in the last quarter. Financial Advocates Investment Management lifted its position in Zimmer Biomet by 3.8% in the 3rd quarter. Financial Advocates Investment Management now owns 2,625 shares of the medical equipment provider’s stock valued at $295,000 after acquiring an additional 97 shares in the last quarter. Finally, Stokes Family Office LLC lifted its position in Zimmer Biomet by 4.1% in the 3rd quarter. Stokes Family Office LLC now owns 2,498 shares of the medical equipment provider’s stock valued at $280,000 after acquiring an additional 99 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Transactions at Zimmer Biomet

In related news, VP Chad F. Phipps sold 26,156 shares of the company’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the transaction, the vice president now owns 44,145 shares in the company, valued at approximately $5,677,929.90. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 0.95% of the stock is owned by company insiders.

Analyst Ratings Changes

ZBH has been the topic of several research reports. Citigroup boosted their price objective on shares of Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research report on Wednesday, April 3rd. Canaccord Genuity Group reaffirmed a “hold” rating and issued a $130.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 23rd. Barclays boosted their price objective on shares of Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a research report on Monday, February 12th. StockNews.com cut shares of Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 19th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a research report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $139.39.

Zimmer Biomet Stock Down 0.3 %

Zimmer Biomet stock opened at $119.35 on Friday. The firm has a market capitalization of $24.52 billion, a PE ratio of 24.41, a P/E/G ratio of 2.20 and a beta of 1.01. The company’s 50-day moving average is $125.98 and its 200-day moving average is $119.52. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $102.00 and a fifty-two week high of $149.25. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.61 and a quick ratio of 0.78.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping the consensus estimate of $2.15 by $0.05. The company had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.93 billion. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. Zimmer Biomet’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.88 EPS. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $0.96 annualized dividend and a dividend yield of 0.80%. Zimmer Biomet’s dividend payout ratio is presently 19.63%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.